Inhalable microspheres embedding chitosan-coated PLGA nanoparticles for 2-methoxyestradiol

References

• Johnson DH. Treatment strategies for metastatic non-small-cell lung cancer. Clin Lung Cancer 1999;1:34–41
   PubMedGoogle Scholar
• Burris HA. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009;28:S4–13
   PubMed Web of Science ®Google Scholar
• Carballo M, Maish MS, Jaroszewski DE, Holmes CE. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothorac Surg 2009;4:13–25
   PubMed Web of Science ®Google Scholar
• Wauthoz N, Deleuze P, Hecq J, et al. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci 2010;39:402–11
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, et al. Inhibition of lung tumour growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010;107:10737–42
   PubMed Web of Science ®Google Scholar
• Tseng CL, Wu SY, Wang WH, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008;29:3014–22
   PubMed Web of Science ®Google Scholar
• Dailey LA, Jekel N, Fink L, et al. Investigation of the pro-inflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006;215:100–8
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Respir Med 2003;97:382–7
   PubMed Web of Science ®Google Scholar
• Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an anti-angiogenic and apoptotic agent, in patients with solid tumours. Cancer Biol Ther 2006;5:22–7
   PubMed Web of Science ®Google Scholar
• Sutherland TE, Anderson RL, Hughes RA. 2-Methoxyestradiol − a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Disc Today 2007;12:13–14
   Google Scholar
• Nafee N, Taet S, Schneider M, et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomed: Nanotechnol Biol Med 2007;3:173–83
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21–32
   PubMed Web of Science ®Google Scholar
• Ravi Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterisation of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004;25:1771–7
   PubMed Web of Science ®Google Scholar
• Ravi Kumar MNV, Mohapatra SS, Kong X, et al. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J Nanosci Nanotechnol 2004;4:1–5
   PubMedGoogle Scholar
• Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005;44:65–73
   PubMed Web of Science ®Google Scholar
• Chung YI, Kim JC, Kim YH, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumour targeting. J Control Release 2010;143:374–82
   PubMed Web of Science ®Google Scholar
• Peltonen L, Valo H, Kolakovic R, et al. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expert Opin Drug Deliv 2010;7:705–19
   PubMed Web of Science ®Google Scholar
• Jensen DK, Jensen LB, Saeid K, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 2012;157:141–8
   PubMed Web of Science ®Google Scholar
• Guo XH, Mei Q, Xin YB, et al. Preparation and cytotoxicity of poly(dl-lactide-co-glycolide) microspheres encapsulating 2-methoxyestradiol. Drug Deliv 2012;19:143–8
   PubMed Web of Science ®Google Scholar
• Guo XH, Xing YB, Mei Q, et al. Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles. Anti-Canc Drugs 2012;23:185–90
   PubMed Web of Science ®Google Scholar
• Diaba R, Brillault J, Bardy A, et al. Formulation and in vitro characterisation of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabiliser: efficiency for ex vivo alveolar macrophage targeting. Int J Pharm 2012;436:833–9
   PubMedGoogle Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009;26:1847–55
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012;33:5574–83
   PubMed Web of Science ®Google Scholar
• Krohn JD, Jensen LB, Koocheki S, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 2012;157:141–8
   PubMed Web of Science ®Google Scholar
• Li YZ, Zhang ZR, Lin Y, Wang CG. Acute lung injury induced by inhalable microparticles in rats. Chin Pharm 2012;J47:1223–6
   Google Scholar
• Krohn JDM, Cun DM, Maltesen MJ, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 2010;142:138–45
   PubMed Web of Science ®Google Scholar
• Elversson J, Millqvist-Fureby A. In situ coating – an approach for particle modification and encapsulation of proteins during spray-drying. Int J Pharm 2006;323:52–63
   PubMed Web of Science ®Google Scholar
• Suarez S, Hickey AJ. Drug properties affecting aerosol behaviour. Respir Care 2000;45:652–66
   PubMedGoogle Scholar
• Munier S, Messai I, Delair T, et al. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. Colloids Surf B Biointerfaces 2005;43:163–73
   PubMed Web of Science ®Google Scholar
• Hara K, Tsujimoto H, Tsukada Y, et al. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008;356:267–73
   PubMed Web of Science ®Google Scholar